Liquidia Technologies (LQDA) Stock Research

Over a week ago

Liquidia price target raised by $55 at H.C. Wainwright, here's why

Jul 23, 11:58 AM

Liquidia just downgraded at BofA, here's why

LQDA

Jun 29, 6:25 AM

Liquidia price target raised by $50 at BTIG, here's why

LQDA

Jun 22, 7:21 AM

Liquidia announces inclusion in S&P SmallCap 600 Index

LQDA

Jun 8, 9:00 AM

S&P SmallCap 600 announces additions, deletions for quarterly rebalance

+26

Jun 5, 5:43 PM

Liquidia price target raised by $8 at H.C. Wainwright, here's why

LQDA

Jun 5, 6:52 AM

Raymond James sees positive readthrough for Liquidia from Hikma v. Amarin

LQDA

Jun 4, 3:27 PM

Liquidia rises 17.6%

LQDA

Jun 4, 12:00 PM

Liquidia price target raised by $12 at H.C. Wainwright, here's why

LQDA

May 12, 10:22 AM

Liquidia price target raised by $11 at Wells Fargo, here's why

LQDA

May 12, 6:28 AM

What You Missed On Wall Street On Monday

+42

May 11, 4:22 PM

Liquidia price target raised by $3 at Jefferies, here's why

LQDA

May 11, 3:19 PM

Midday Fly By: Dream Finders offers to buy Beazer, Fox reports Q3 beat

+26

May 11, 12:02 PM

Liquidia reports Q1 EPS 52c, consensus 41c

LQDA

May 11, 6:32 AM

United Therapeutics price target raised by $20 at Wells Fargo, here's why

Mar 23, 6:28 AM

Liquidia price target raised by $7 at Wells Fargo, here's why

Mar 23, 6:27 AM

Insmed price target lowered by $33 at Wells Fargo, here's why

Mar 23, 6:27 AM

Liquidia Technologies put volume heavy and directionally bearish

LQDA

Mar 16, 10:55 AM

Liquidia price target raised by $3 at Oppenheimer, here's why

LQDA

Mar 12, 7:45 AM

Liquidia rises 7.7%

LQDA

Mar 6, 10:01 AM

Liquidia price target raised by $5 at H.C. Wainwright, here's why

LQDA

Mar 6, 6:11 AM

Liquidia files automatic mixed securities shelf

LQDA

Mar 5, 4:41 PM

Liquidia reports Q4 EPS 15c, consensus 33c

LQDA

Mar 5, 6:32 AM

Liquidia reaction on United Therapeutics' TreSMI reveal 'overdone,' says Needham

Feb 25, 12:49 PM

Proprietary PRINT Technology Platform: Their unique particle engineering technology allows for precise drug formulation and delivery, creating innovative product opportunities.

Strong Intellectual Property and Exclusivity: Extensive patent portfolio protecting their PRINT technology and specific drug formulations, coupled with YUTREPIA's orphan drug designation.

Advantageous Product Profile for YUTREPIA: YUTREPIA (treprostinil inhalation powder) offers a dry powder, room-temperature stable, and potentially easier-to-administer alternative for pulmonary arterial hypertension (PAH) patients.

Regulatory & Patent Litigation Risks: The ongoing patent dispute with United Therapeutics, particularly the 'stay' on final FDA approval for YUTREPIA, poses significant regulatory and commercialization hurdles that could delay or prevent market entry.

Commercialization & Market Adoption Risks: Even with full regulatory approval, successful market launch, physician adoption, payor coverage, and patient uptake of YUTREPIA are uncertain and depend on many factors.

Intense Competition Risks: Liquidia faces strong competition from established companies, primarily United Therapeutics, with existing approved products for pulmonary hypertension that are well-entrenched in the market.

Charts

Proprietary PRINT Technology Platform: Their unique particle engineering technology allows for precise drug formulation and delivery, creating innovative product opportunities.

Strong Intellectual Property and Exclusivity: Extensive patent portfolio protecting their PRINT technology and specific drug formulations, coupled with YUTREPIA's orphan drug designation.